How Has the Daratumumab Or Darzalex Market Evolved Historically and What is its Current Size?
The daratumumab or darzalex market has seen considerable growth due to a variety of factors.
• The market for daratumumab, also known as darzalex, has seen significant expansion in the past few years. It is forecasted to rise from a worth of $5,093.04 million in 2024 to $5,618.30 million in 2025, representing a compound annual growth rate (CAGR) of 10.3%.
The upward trend in the historical period can be explained by the utilization of various research channels, improved feasibility of biomanufacturing processes, an increased reliance on monoclonal antibodies, the implementation of more strategic initiatives, and greater mAbs production.
What is the Forecasted Market Size and CAGR for the Daratumumab Or Darzalex Market Size Evolve over the Forecast Period?
The daratumumab or darzalex market is expected to maintain its strong growth trajectory in upcoming years.
• Rapid expansion is anticipated in the daratumumab or darzalex market in the coming years, with projections indicating growth to $8,189.36 million in 2029 with a compound annual growth rate (CAGR) of 10.0%.
This expected growth during the forecast period can be linked to factors such as increasing clinical proof, higher levels of early treatment implementation, rising biologics demand, heightening patient awareness, increasing blood cancer rates, and growing chronic disease prevalence. Further influencing trends during the forecast period include technological progression, the launch of new products, the provision of diverse products and services, strategic partnerships, mergers and acquisitions, advancements in radiation technologies, and collaborations.
Which Drivers Are Accelerating Growth In The Daratumumab Or Darzalex Market?
The daratumumab or darzalex market is expected to grow due to an increase in bone marrow cancer incidences. Bone marrow cancer such as leukemia and multiple myeloma start from the bone marrow and affect the normal functioning of the body due to abnormal blood cell production. This surge in the occurrence of bone marrow cancer can be tied to better detection methods, an aging society, and contributory factors like environmental factors, genetic predispositions, and lifestyle choices. In the treatment of multiple myeloma, a form of bone marrow cancer, Daratumumab (Darzalex) is helpful as it attacks and kills abnormal plasma cells in the marrow. For example, projections from the American Cancer Society in 2024 revealed that there were expected to be 89,190 lymphoma cases, compared to 89,010 in 2022, and 35,780 myeloma cases, a rise from 34,470 in 2022. Consequently, the increase in bone marrow cancer is fuelling the growth of the daratumumab or darzalex market. The uptake of biologics and targeted therapies is set to push the daratumumab or darzalex market's growth. Drugs or other substances that specifically identify and combat specific molecules vital for the growth and survival of cancer or other diseases are used in targeted therapies. The prevalence of chronic ailments and advancements in precision medicine, which allow for more individualized, efficient treatments, are driving the rise in adoption of biologics and targeted therapies. Daratumumab is employed in targeted therapies due to its unique effect on CD38, a protein highly expressed on the surface of malignant plasma cells in multiple myeloma. According to the Advanced Therapy Treatment Centers (ATTC), investments in advanced therapies saw a 31% annual increase in 2022, with the UK responsible for 14% of all global commercial ATMP clinical trials. Thus, the uptake of biologics and targeted therapies is contributing to the growth of the daratumumab or darzalex market.
What Are The Market Segments In The Daratumumab Or Darzalex Market?
The daratumumab or darzalex market covered in this report is segmented –
1) By Drug Type: 100Mg Injection, 400Mg Injection
2) By Distribution Channel: Pharmacies, Hospital, Other Distribution Channels
3) By Application: Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Diffuse Large B Cell Lymphoma, Other Applications
Pre-Book The Daratumumab Or Darzalex Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Daratumumab Or Darzalex Market?
The prevailing trend in the daratumumab or darzalex market is the focus on a move towards early intervention methods in oncology treatments. This includes strategies such as combination therapies, which are designed to increase effectiveness in the treatment of multiple myeloma and various other forms of cancer. Combination therapies involve the use of two or more therapeutic agents, which operate through different mechanisms of action and are often used in a synergistic manner. The goal of this is to enhance effectiveness, reduce resistance, and enhance patient results, whilst potentially decreasing the adverse effects when compared to monotherapy. For example, in July 2024, Johnson & Johnson, a pharmaceutical company based in the US, obtained approval from the U.S. FDA for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) to be used in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation therapy in newly diagnosed multiple myeloma (NDMM) patients eligible for autologous stem cell transplant (ASCT). This new approval provides a four-pronged treatment approach at the initial diagnosis stage, offering a potential improvement in patient outcomes.
Who Are the Key Players In The Daratumumab Or Darzalex Market?
Major companies operating in the daratumumab or darzalex market include:
• Genmab A/S
• Janssen Biotech Inc.
What Are The Regional Insights Into The Daratumumab Or Darzalex Market?
North America was the largest region in the daratumumab or darzalex market in 2024. The regions covered in the daratumumab or darzalex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
